CCT-367766|PROTACs|CAS 2229856-58-8|DC Chemicals

Cas No.:	2229856-58-8
Chemical Name:	N-(2-Chloro-5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)phenyl)-2-((4-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)methyl)quinoline-6-carboxamide
Synonyms:	CCT367766;CCT 367766
SMILES:	N1C2C(=CC(C(NC3=CC(NC(C4=CC=C5C(=C4)OCCO5)=O)=CC=C3Cl)=O)=CC=2)C=CC=1CN1CCN(CCOCCOCCOC2=CC=CC3=C2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1
Formula:	C₄₉H₄₈ClN₇O₁₁
M.Wt:	946.41
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	[1]. Chessum NEA, et al. Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766).J Med Chem. 2018 Feb 8;61(3):918-933.

Description:	CCT-367766 (CCT367766) is a novel heterobifunctional PROTAC that binds and degrades the putative transcription factor regulator Pirin in cells.
Target:	CRBN-DDB1:490 nM (IC50)
In Vitro:	CCT367766 (50-1500 nM; 24 hours) demonstates the depletion of pirin protein as a the time-dependent hook-effect in SK-OV-3 human ovarian cancer cells[1]. CCT367766 (0.5-50 nM; 2 hours) demonstrates the concentration-dependent depletion of pirin protein after 2 h exposure in SK-OV-3 cells[1]. Western Blot Analysis[1] Cell Line: SK-OV-3 human ovarian cancer cells Concentration: 50, 150, 250, 500 and 1500 nM Incubation Time: 2 hours, 4 hours, 24 hours Result: Decreased pirin protein expression. Western Blot Analysis[1] Cell Line: SK-OV-3 human ovarian cancer cells Concentration: 0.5, 1, 2.5, 5, 7.5, 10, 25, and 50 nM Incubation Time: 2 hours Result: Completely degraded pirin just at 50 nM treatment.
References:	[1]. Chessum NEA, et al. Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766).J Med Chem. 2018 Feb 8;61(3):918-933.

Cat. No.	Product name	Field of application
DC65211	KT-474	KT-474 is a highly active and selective, orally bioavailable IRAK4 degrader being developed for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven immune-inflammatory diseases.
DC39826	Homo-PROTAC cereblon degrader 1	Homo-PROTAC cereblon degrader 1, is a cereblon degrader.
DC74523	XY-07-35	XY-07-35 is a potent, selective HDAC6 proteolysis targeting chimera (PROTAC) degrader with IC50 of 48.5 nM.
DC74496	HJM-561	HJM-561 is a potent, selective and orally bioavailable EGFR PROTAC degrader, selectively degrades the EGFR C797S-containing triple mutants Del19/T790M/C797S and L858R/T790M/C797S with DC50 values of 9.2 nM and 5.8 nM, respectively.
DC74494	GNE-0011	GNE-0011 is a monovalent, JQ1-based BRD4 degrader that is not linked to an E3 ligase binder, triggers proteasomal and ubiquitin-dependent selective degradation of BRD4 over BRD2 and BRD3.
DC74479	BSJ-05-037	BSJ-05-037 is a potent and selective heterobifunctional degrader of ITK with DC50 of 17.6-41.8 nM in TCL lines DERL-2 and Hut78.
DC72756	JQAD1	JQAD1 is a CRBN-dependent PROTAC that selectively targets EP300 for degradation. JQAD1 suppresses EP300 expression and the H3K27ac modification. JQAD1 induces apoptosis. JQAD1 can be used in research of cancer.
DC48434	TD-165	TD165(TD 165) is a PROTAC-based cereblon (CRBN) degrader that degrads Cav1.2α with the DC50 of 20.4 nM, comprising a cereblon (CRBN) ligand binding group, a linker and an von Hippel-Landau (VHL) binding group.
DC46405	ARD-2128	ARD2128 is a highly potent, orally bioavailable PROTAC androgen receptor (AR) degrader. ARD-2128 effectively reduces AR protein, suppresses AR-regulated genes in tumor tissues, and inhibits growth of tumor without signs of toxicity. ARD-2128 has the potential for the research of the prostate cancer.
DC46309	Boc-piperazine-benzoic acid	Boc-piperazine-benzoic acid is a PROTAC linker and can be used in the synthesis of PROTACs, such as PROTAC androgen receptor (AR) degrader ARD-2128.